Bone Biologics Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting continued operating losses and no revenues, with 3,389,057 shares of common stock outstanding as of October 26, 2026.

Key Highlights

  • No revenues: The company reported $0 in revenues for both the three and nine months ended September 30, 2026, according to the filing.
  • Nine-month net loss: Net loss for the nine months ended September 30, 2026 was $2,157,341, compared to $2,424,348 for the same period in 2025.
  • Q3 net loss: Net loss for the three months ended September 30, 2026 was $617,651, versus $666,737 in the prior-year quarter.
  • Cash position: Cash stood at $6,088,085 as of September 30, 2026, up from $5,334,322 at December 31, 2025.
  • Share count increase: Common shares issued and outstanding rose to 3,389,057 at September 30, 2026, from 1,795,260 at December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $90,287,710 as of September 30, 2026, compared to $88,130,369 at December 31, 2025.
  • Total assets: Total assets were $6,432,445 at September 30, 2026, against total liabilities of $480,775, leaving total stockholders' equity of $5,951,670.

Bone Biologics Reports Continued Operating Losses and Zero Revenue Through September 2026

Bone Biologics Corporation (NASDAQ:BBLG), a Delaware corporation headquartered in Burlington, Massachusetts, filed its quarterly report covering the period ended September 30, 2026. The company, which is classified as a non-accelerated filer and a smaller reporting company, reported no revenues in either the three-month or nine-month periods covered by the filing. Total operating expenses for the nine months ended September 30, 2026 were $2,279,501, comprised of $692,914 in research and development expenses and $1,586,587 in general and administrative expenses, according to the filing.

For the three months ended September 30, 2026, total operating expenses were $666,340, including $242,569 in research and development and $423,771 in general and administrative costs. The company's loss from operations for the nine-month period was $2,279,501, partially offset by other income of $122,160, which included $121,655 in interest income and $505 from the change in fair value of the warrant liability. The resulting net loss for the nine months was $2,157,341, or $0.88 per share on a basic and diluted basis, based on weighted average shares outstanding of 2,445,496.

On the balance sheet, cash increased to $6,088,085 at September 30, 2026, from $5,334,322 at December 31, 2025. Deferred offering costs of $52,666 appeared on the September 30, 2026 balance sheet, with no comparable amount at year-end 2025. The common share count grew from 1,795,260 to 3,389,057 during the nine-month period, and additional paid-in capital rose from $93,506,122 to $96,235,991. The filing notes that the company's forward-looking statements are subject to risks including its "ability to raise additional capital to fund our operations" and "obtaining Food and Drug Administration and other regulatory authorization to market our drug and biological products," among other factors cited in the company's cautionary language.

What Was Disclosed

Bone Biologics Corporation disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026, showing no revenues, a nine-month net loss of $2,157,341, cash of $6,088,085, and an accumulated deficit of $90,287,710.